Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists
| Autor: | Amit Dutt Dwary, Kayathanahalli Govindachar Srinivas, Ajay Bapna, Suresh H. Advani, Nagendra Ramanjinappa, Unni S. Pillai, Vamshi Krishna, P. Vijay Anand Reddy, Anjana Joel, Manikandan Dhanushkodi, Smruti B. Koppikar, Dinesh Chandra Doval, S. V. S. S. Prasad, Prasad Narayanan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Advanced ovarian cancer
medicine.medical_specialty Bevacizumab business.industry Obstetrics and Gynecology Scientific evidence 03 medical and health sciences 0302 clinical medicine Oncology Surgical oncology 030220 oncology & carcinogenesis Medicine In patient 030212 general & internal medicine Treatment decision making business Intensive care medicine medicine.drug |
| Zdroj: | Indian Journal of Gynecologic Oncology. 19 |
| ISSN: | 2363-8400 2363-8397 |
| DOI: | 10.1007/s40944-020-00485-6 |
| Popis: | Purpose To discuss and reach a consensus on the use of bevacizumab in women with advanced ovarian cancer in Indian settings. Methods An advisory board meeting comprising Indian oncologists was convened to review key literature available on the role of bevacizumab in the management of advanced ovarian cancer. Key recommendations were devised via consensus by the expert panel based on the analysis of available scientific evidence and clinical experience. Results The expert panel recommends the use of bevacizumab in patients with advanced ovarian cancer in first-line settings, as well as in recurrent settings. Conclusion This document summarizes key discussion points and recommendations provided by the advisory panel, which helps guide clinicians on the use of bevacizumab for managing advanced ovarian cancer in the Indian setting. It also acts as a pragmatic tool to assist clinicians in making appropriate treatment decisions with respect to advanced ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink